牛牛AI助理已提取核心訊息
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 6,095 shares of common stock on March 4, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $9,310.72. Following the sale, Obenshain's direct holdings in the company amount to 279,998 shares of common stock.
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年3月4日完成了6,095股普通股的出售。該交易在公開市場上進行，股票以每股1.5276美元的價格出售，總銷售價值爲9,310.72美元。出售後，Obenshain在該公司的直接持有量爲279,998股普通股。
藍鳥生物公司總裁兼首席執行官安德魯·奧本沙因於2024年3月4日完成了6,095股普通股的出售。該交易在公開市場上進行，股票以每股1.5276美元的價格出售，總銷售價值爲9,310.72美元。出售後，Obenshain在該公司的直接持有量爲279,998股普通股。
有用
沒用